This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Calendar: Key Dates for October

BOSTON ( TheStreet) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions.

Phase III or pivotal studies that could report results in October:

  • Bristol-Myers (BMY) Squibb's melanoma drug ipilimumab.
  • Corcept Therapeutics' (CORT) Corlux in Cushing's syndrome.
  • Seattle Genetics' (SGEN) brentuximab vedotin in anaplastic large cell lymphoma.
  • Cyclacel Pharmaceuticals' (CYCC) seliciclib in non-small cell lung cancer.

Oct. 1

FDA drug approval decision: Hospira' (HSP) Dyloject for acute moderate-to-severe pain in adults.

FDA drug approval decisions: Johnson & Johnson (JNJ) Nucynta for pain indications.

Oct. 4

FDA drug approval decision: Human Genome Sciences' (HGSI) Zalbin for hepatitis C.

Oct. 8-12

European Society for Medical Oncology annual meeting. Data presentations to include Johnson & Johnson (JNJ) (abiraterone), Oxigene (OXGN) (Zybrestat), Seattle Genetics (SGN-75), Allos Therapeutics (ALTH) (Folotyn) and Arqule (ARQL) (ARQ197).

The Obesity Society annual meeting. Stocks of interest include Arena Pharmaceuticals (ARNA), Vivus (VVUS) and Orexigen Therapeutics (OREX).

Oct. 11

FDA drug approval decision: Alexza Pharmaceuticals' (ALXA) AZ-004 for agitation in patients with schizophrenia or bipolar disorder.

FDA drug approval decision: Jazz Pharmaceuticals' (JAZZ) JZP-6 for fibromyalgia.

Oct. 12

FDA drug approval decision: Alkermes (ALKS) Vivitrol for opioid addiction.

Oct 13-16

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Data presentations to include Sanofi-Aventis (SNY) (Teriflunomide), Biogen Idec (BIIB) and Elan (ELN) (Tysabri) and Genzyme (GENZ) (Campath).

Oct. 18

FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure. Amgen (AMGN) (Aranesp, Epogen), Johnson & Johnson (Procrit) and Affymax (AFFY) (Hematide).

Oct. 19

BioMarin Pharmaceuticals (BMRN) analyst/investor day.

Oct. 20

Genzyme third-quarter earnings announcement.

Oct. 22

FDA drug approval decision: Arena Pharmaceuticals' (ARNA) lorcaserin for obesity

FDA drug approval decision: Amylin Pharmaceuticals (AMLN), Alkermes and Eli Lilly's (LLY) Bydureon for diabetes.

Oct. 28

FDA drug approval decision: Vivus' (VVUS) Qnexa for obesity.

Oct. 29

FDA drug approval decision: Avanir Pharmaceuticals' (AVNR) Zenvia for pseudobulbar affect.

FDA drug approval decision: Forest Labs (FRX) ceftaroline for Community Acquired Pneumonia. Oct. 30

FDA drug approval decision: Biodel's (BIOD) Linjeta for diabetes.

Exact Sciences (EXAS) presentation of external validation study of its genetic stool test for colon cancer.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs